Effects of Green Tea on Cardiometabolic Outcomes

March 24, 2025 updated by: Jonathan Sinclair, University of Central Lancashire

Effects of Green Tea Supplementation on Cardiometabolic Parameters

Cardiovascular disease, type 2 diabetes mellitus and associated diseases combined are the leading health burden and cause of mortality worldwide; therefore, the necessity for an intervention is paramount. Dietary interventions to improve cardiometabolic health are highly sought after as they possess less risk than pharmacological drugs. It has been postulated that Green tea may be beneficial in improving cardiometabolic outcomes. However, to date, no research has explored this using a placebo randomized intervention.

Study Overview

Status

Not yet recruiting

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Lancashire
      • Preston, Lancashire, United Kingdom, PR4 0PE
        • University of Central Lancashire
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Healthy
  • Between 18 & 65 years
  • Non-smoker
  • BMI < 30
  • Able to give informed consent

Exclusion Criteria:

  • Pregnancy
  • Diabetes or any other metabolic/ uncontrolled hypertensive conditions
  • Food allergies to quercetin
  • Habitual consumption of quercetin
  • Not regularly taking medication or antioxidant supplements

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Green tea
Green tea tablets 1000mg 1 x per day
Green tea tablets 1000mg 1 x per day
Placebo Comparator: Placebo
Placebo control 1 x blinded placebo tablet per day
Placebo control 1 x blinded placebo tablet per day

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Systolic blood pressure
Time Frame: Baseline
Systolic blood pressure - measured using a digital blood pressure monitor
Baseline
Systolic blood pressure
Time Frame: 20 days
Systolic blood pressure - measured using a digital blood pressure monitor
20 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percent bodyfat
Time Frame: Baseline
Participants percentage composition of fat - measured using bio-electrical impedance
Baseline
Percent bodyfat
Time Frame: 20 days
Participants percentage composition of fat - measured using bio-electrical impedance
20 days
Waist to hip ratio
Time Frame: Baseline
Ratio of waist to hip circumference - measured using anthropocentric tape
Baseline
Waist to hip ratio
Time Frame: 20 days
Ratio of waist to hip circumference - measured using anthropocentric tape
20 days
Blood glucose
Time Frame: Baseline
Capillary blood glucose - mmol/L
Baseline
Blood glucose
Time Frame: 20 days
Capillary blood glucose - mmol/L
20 days
Blood triglycerides
Time Frame: Baseline
Capillary blood triglycerides - mmol/L
Baseline
Blood triglycerides
Time Frame: 20 days
Capillary blood triglycerides - mmol/L
20 days
Blood cholesterol (Total, HDL & LDL)
Time Frame: Baseline
Capillary blood cholesterol - mmol/L
Baseline
Blood cholesterol (Total, HDL & LDL)
Time Frame: 20 days
Capillary blood cholesterol - mmol/L
20 days
State Trait Anxiety Inventory
Time Frame: Baseline
Psychological wellbeing - the state trait anxiety inventory is a 40 item questionnaire with each question having a 1-4 score system, thus the maximum score is 80 which indicates the highest level of anxiety.
Baseline
State Trait Anxiety Inventory
Time Frame: 20 days
Psychological wellbeing - the state trait anxiety inventory is a 40 item questionnaire with each question having a 1-4 score system, thus the maximum score is 80 which indicates the highest level of anxiety.
20 days
Insomnia Severity Index
Time Frame: Baseline
Sleep quality - The Insomnia Severity Index is a brief instrument designed to assess the severity of both nighttime and daytime components of insomnia. The Insomnia Severity Index is a 7-item self-report questionnaire yielding a total score ranging from 0 to 28.
Baseline
Insomnia Severity Index
Time Frame: 20 days
Sleep quality - The Insomnia Severity Index is a brief instrument designed to assess the severity of both nighttime and daytime components of insomnia. The Insomnia Severity Index is a 7-item self-report questionnaire yielding a total score ranging from 0 to 28.
20 days
Pittsburgh Sleep Quality Index
Time Frame: Baseline
Sleep quality - The Pittsburgh Sleep Quality index, is a questionnaire that consists of 19 self-rated questions, grouped into 7 components. Each component is scored separately, weighted equally on a 0 - 3 scale and the scores of the 7 components are then added to give a global score, which has a range of 0 - 21 with higher scores indicating worse sleep quality.
Baseline
Pittsburgh Sleep Quality Index
Time Frame: 20 days
Sleep quality - The Pittsburgh Sleep Quality index, is a questionnaire that consists of 19 self-rated questions, grouped into 7 components. Each component is scored separately, weighted equally on a 0 - 3 scale and the scores of the 7 components are then added to give a global score, which has a range of 0 - 21 with higher scores indicating worse sleep quality.
20 days
Epworth Sleepiness Scale
Time Frame: Baseline
Sleep quality - The Epworth Sleepiness Scale is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3) with a maximum score of 24.
Baseline
Epworth Sleepiness Scale
Time Frame: 20 days
Sleep quality - The Epworth Sleepiness Scale is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3) with a maximum score of 24.
20 days
Triglyceride glucose index
Time Frame: Baseline
Calculated as the natural logarithm of (blood triglycerides x blood glucose) /2)
Baseline
Triglyceride glucose index
Time Frame: 20 days
Calculated as the natural logarithm of (blood triglycerides x blood glucose) /2)
20 days
Diastolic blood pressure
Time Frame: Baseline
Diastolic blood pressure - measured using a digital blood pressure monitor
Baseline
Diastolic blood pressure
Time Frame: 20 days
Diastolic blood pressure - measured using a digital blood pressure monitor
20 days
Coop-Wonka chart
Time Frame: Baseline
Psychological wellbeing - The Coop-Wonka chart is a six item questionnaire with a 1-5 scoring
Baseline
Coop-Wonka chart
Time Frame: 20 days
Psychological wellbeing - The Coop-Wonka chart is a six item questionnaire with a 1-5 scoring
20 days
Beck Depression Inventory
Time Frame: Baseline
sychological wellbeing - the Beck Depression Inventory is a 21 questionnaire with questions that range in scoring from 0-3, thus the maximum score is 63 which is the highest depression score possible.
Baseline
Beck Depression Inventory
Time Frame: 20 days
sychological wellbeing - the Beck Depression Inventory is a 21 questionnaire with questions that range in scoring from 0-3, thus the maximum score is 63 which is the highest depression score possible.
20 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 1, 2025

Primary Completion (Estimated)

February 1, 2027

Study Completion (Estimated)

June 1, 2027

Study Registration Dates

First Submitted

January 21, 2025

First Submitted That Met QC Criteria

January 21, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 27, 2025

Last Update Submitted That Met QC Criteria

March 24, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • Green tea cardiometabolic

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiometabolic Syndrome

Clinical Trials on Placebo

Subscribe